Introspect believes that high-quality digital combination therapies will increase the safety and effectiveness of many mental health drugs. Digital therapeutics (DTx) will provide personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles…

entheogenixbio.com

InnarisBio specialized in drug formulation bringing its sol-gel based, intranasal excipient technology to atai. The novel technology may enable new drug formulations with unique and optimized modes of delivery across various active ingredients in the atai pipeline, as well as potential assets in the future. 

innaris.bio

PsyProtix is taking a precision psychiatry approach to develop metabolomics-based biomarkers to stratify patients with treatment-resistant depression (TRD) and other mental health indications. By identifying patient subsets with unique metabolic profiles, PsyProtix will test mechanism-based treatments with the goal of improving overall outcomes.